Author:
Ancel Julien,Dormoy Valérian,Raby Béatrice Nawrocki,Dalstein Véronique,Durlach Anne,Dewolf Maxime,Gilles Christine,Polette Myriam,Deslée Gaëtan
Abstract
Lung cancer remains the first cause of cancer-related death despite many therapeutic innovations, including immune checkpoint inhibitors (ICI). ICI are now well used in daily practice at late metastatic stages and locally advanced stages after a chemo-radiation. ICI are also emerging in the peri-operative context. However, all patients do not benefit from ICI and even suffer from additional immune side effects. A current challenge remains to identify patients eligible for ICI and benefiting from these drugs. Currently, the prediction of ICI response is only supported by Programmed death-ligand 1 (PD-L1) tumor expression with perfectible results and limitations inherent to tumor-biopsy specimen analysis. Here, we reviewed alternative markers based on liquid biopsy and focused on the most promising biomarkers to modify clinical practice, including non-tumoral blood cell count such as absolute neutrophil counts, platelet to lymphocyte ratio, neutrophil to lymphocyte ratio, and derived neutrophil to lymphocyte ratio. We also discussed soluble-derived immune checkpoint-related products such as sPD-L1, circulating tumor cells (detection, count, and marker expression), and circulating tumor DNA-related products. Finally, we explored perspectives for liquid biopsies in the immune landscape and discussed how they could be implemented into lung cancer management with a potential biological–driven decision.
Funder
Université de Reims Champagne-Ardenne
Institut National de la Santé et de la Recherche Médicale
Subject
Immunology,Immunology and Allergy
Reference193 articles.
1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J Clin,2018
2. Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment;Duma;Mayo Clin Proc,2019
3. Precision diagnosis and treatment for advanced non-Small-Cell lung cancer;Reck;N Engl J Med,2017
4. Biomarkers that currently affect clinical practice in lung cancer: EGFR, ALK, MET, ROS-1, and KRAS;Korpanty;Front Oncol,2014
5. Predictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancer;Prelaj;Eur J Cancer,2019